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Abstract
Anemia is a common complication of chronic kidney disease (CKD) associated with
disease progression and increased mortality. This anemia is mainly due to inadequate
production of erythropoietin (EPO) by the failing kidneys, resulting from the reduction
in renal EPO-producing cells (REPC) or from dysregulation of the hypoxia-inducible
factor (HIF) system that regulates several genes related to hypoxia, angiogenesis, fibro-
sis and glucose metabolism, among others. In this chapter, we present a review on the
HIF system in CKD-anemia, the HIF response to erythropoiesis-stimulating agents
(ESA) therapy and its potential involvement in the development of ESA resistance by
enhancing kidney fibrosis and inflammation. Due to concerns related to ESA use, new
drugs to correct anemia are under study, being the prolyl hydroxylase inhibitors the
most promising candidates.
Keywords: chronic kidney disease, erythropoietin resistance, fibrosis, HIF system,
Hypoxia, inflammation
1. Introduction
Anemia is a common complication of chronic kidney disease (CKD) that often develops early
in the course of the disease, and its frequency and severity increase with the decline of renal
function [1]. This condition is associated with a decreased quality of life [2, 3], increased
hospitalizations and comorbidities [4, 5], progression of renal dysfunction [6–8], enhanced
cardiovascular complications [9, 10] and mortality [11–13]. The main cause for anemia in
CKD patients is erythropoietin (EPO) deficit, due to decreased hormone production by the
failing kidneys; other factors can also contribute to the development or worsening of CKD-
anemia, such as iron deficiency, inflammation and uremic toxins, among others [14].
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EPO is a glycoprotein that presents several functions acting as a hormone, cytokine or growth
factor on target cells that express the EPO receptors (EPOR), through different pathways. In
the bone marrow, EPO controls cell proliferation, differentiation and death of erythroid cells.
During fetal life, the majority of EPO is produced by the liver; after birth there is a switch to
renal production, and in the adulthood, 90% of this hormone is produced by the kidneys,
whereas the liver is a secondary site of production [15]. EPO is also expressed in the brain,
spleen, lung and testis, but its contribution to serum EPO levels is not clarified [16]. The kidney
cells responsible for EPO production are still under debate, but several studies showed that
renal EPO-producing cells (REPC) include the peritubular fibroblast-like interstitial cells in the
inner cortex and in the outer medulla [17, 18], the proximal and distal convoluted tubules and
cortical collecting ducts [19]. REPC are sensitive to changes in oxygen (O2) tension, and in
conditions of hypoxia, the kidney responds increasing the number of REPC capable of pro-
ducing EPO [20].
In CKD, the severity of the disease defines the kidney capacity to produce EPO [21, 22].
Indeed, patients with GFR >30mL/min/1.73m2 are still able to induce a physiologic response
to anemia, showed by the normal or even elevated serum EPO levels [23, 24]. Nevertheless,
serum EPO levels may not be sufficient for the degree of anemia; actually, anemic patients with
normal renal function may present a 10-fold to 100-fold increase in serum EPO levels [25, 26],
to achieve correction of anemia.
The kidney is the major site of EPO production in the adults; however, it is possible that
extrarenal sites contribute for the marked rise in plasma EPO in end-stage renal disease (ESRD)
patients [27], as already showed in animal models of kidney injury [28, 29]. It was also
reported that patients with anemia can switch EPO production from the kidney to the liver
[30, 31], as can be shown by glycoform analysis of EPO. Indeed, the posttranslational EPO
glycosylation is specific of the synthesizing cells, giving rise to different EPO glycoforms that
can be used to localize EPO synthesis [30, 32].
Hypoxia regulates the EPO gene through the hypoxia-inducible factor (HIF) system [20]. This
HIF system includes O2-dependent HIF-1α, HIF-2α (also known as endothelial PAS domain-
containing protein 1) and HIF-3α subunits, and the constitutively expressed HIF-1β and HIF-
2β subunits (also known as aryl hydrocarbon receptor nuclear translocator). The HIF-α sub-
units are hydroxylated in specific proline residues, by the prolyl-4-hydroxylase (PHD) proteins
that require O2 as a co-substrate (Figure 1). The hydroxylated HIF-α subunit targets the von
Hippel-Lindau tumor suppressor protein (VHL) to be recognized by an ubiquitin ligase com-
plement that will induce a rapid ubiquitination and proteasomal degradation of HIF-α sub-
units. Under normoxia, HIF-α subunits are almost undetectable, but in hypoxic conditions, the
hydroxylation by PHD proteins is inhibited; thus, the HIF-α accumulates in the cytoplasm, is
translocated to the nucleus and binds to the HIF-β subunit, forming a complex that recruits the
coactivators P300/CBP and activates the transcription of several genes [20].
Several genes are regulated by the HIF-1α and HIF-2α subunits (Figure 1), but recent studies
showed that HIF-2α is the main regulator of EPO synthesis in the kidney and liver [33–35] and
is also important for the regulation of several factors involved in iron homeostasis, as iron is an
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important element for hemoglobin (Hb) synthesis [36]. The HIF-1α subunit activates the
transcription of glucose metabolism, angiogenesis and fibrosis related genes to promote
wound healing [37]. The role of HIF-3α is still ambiguous and under current investigation. It
is known that HIF-3α presents several isoforms with different roles [38]; the up-regulation of
some HIF-3α isoforms appears to act as a negative feedback mechanism to regulate HIF-1α
and/or HIF-2α subunits; however, recent studies showed that HIF-3αmight share with HIF-1α
the regulation of some genes [39].
This chapter reviews the HIF response to erythropoiesis-stimulating agents (ESA) therapy
focusing on its potential involvement in the development of ESA resistance, by enhancing
kidney fibrosis and inflammation.
2. Hypoxia and progression of renal disease
Renal hypoxia is well known as an important contributor for the progression of renal disease.
A study conducted in a rat model of diabetic nephropathy reported that intrarenal hypoxia
develops early in the course of the disease and precedes the alterations in circulating bio-
markers of kidney damage [40]. Irrespective of the initial cause of CKD, the histopathological
Figure 1. Regulation of hypoxia-inducible system. (A) In conditions of normoxia, the HIF-α subunits are hydroxylated, in
specific proline residues by prolyl-4-hydroxylase (PHD) proteins, which recruit the von Hippel-Lindau tumor suppressor
protein (VHL) a signal for rapid ubiquitination and proteasomal degradation of HIF-α subunits. PHD inhibitors are under
development, as they might impair the degradation of the HIF-α subunits, improving anemia. (B) Under hypoxic
conditions, the PHD proteins are inhibited, and consequently, the HIF-α subunits are not targeted by VHL protein for
degradation, translocating to the nucleus and binding to the HIF-β subunit, forming a complex that recruit the
coactivators P300/CBP, leading to the transcription of several genes that will depend on the type of HIF-α subunit (HIF-
1α or HIF-2a) that binds to the target gene sequences. There is a crosstalk between hypoxia and inflammation, leading to
the activation of the nuclear factor kappa beta (NF-κB) pathway that can also induce HIF-1α accumulation.
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analysis of renal biopsies showed that fibrosis is the common final pathway [41]. The underly-
ing mechanisms are still debatable.
Glomerular injury leads to a reduction in glomerular blood flow and consequently limits blood
flow into peritubular capillaries, causing hypoxia and tubulointerstitial injury [42]. After an
initial injury, the tubular cells will attempt to correct and repair the injury by recruiting and
activating several cells, such as macrophages, fibroblasts and epithelial tubular cells that will
release pro-inflammatory cytokines and fibrosis factors, and contribute to excessive interstitial
extracellular matrix (ECM) accumulation and expansion. Transforming growth factor beta
(TGF-β), a recognized pro-fibrotic factor, appears to be central for fibroblast activation, prolif-
eration and transdifferentiation, contributing to ECM deposition [43]. TGF-β also presents
immunomodulatory effects on macrophages and monocyte recruitment, leading to the pro-
duction of inflammatory cytokines [44]. In early renal injuries, M2-type macrophages are
recruited to promote tissue remodeling; however, if the injury is continuous, more inflamma-
tory monocytes will be recruited differentiating their phenotype into M1-type macrophages,
responsible for the release of pro-inflammatory cytokines (such as tumor necrosis factor [TNF-
α], interferon [IFN]-γ, interleukin (IL)-1β and IL-6) and cell apoptosis [45]. The release of these
pro-inflammatory cytokines leads to the activation of the nuclear factor kappa B (NF-κB)
pathway, thus amplifying the inflammatory process [44]. The continuous activation of this
system will culminate with the formation of scar tissue or fibrosis. The presence of fibrotic
tissue reduces the diffusion of O2, which will further aggravate the hypoxic environment.
Anemia caused by inadequate EPO production by the kidneys also contributes to renal hyp-
oxia. However, the mechanisms underlying the reduced capacity for EPO production by the
REPC are not well understood. It has been proposed that after renal injury, REPC can suffer a
transdifferentiation, called epithelial to mesenchymal transition (EMT), into myofibroblasts,
losing their capacity to synthesize EPO and increasing the synthesis of collagen, contributing
to the expansion of ECM [46]. Nevertheless, this EMT phenomenon was never proved in
humans. The residual capacity to increase serum EPO levels when subjected to hypoxic
environment or high altitudes by renal patients, even those on dialysis [47], indicates that a
dysregulation of the HIF system, more than a complete loss of REPC cells, could be responsible
for the reduced EPO production. Moreover, the pharmacological inhibition of the PHD in CKD
patients stimulates endogenous EPO production further supporting a deranged oxygen sens-
ing [27]. A recent study in mice by Souma et al. [48] also strengthened this hypothesis, by
showing that inflammatory cytokines and/or fibrosis factors suppress HIF activation through
the over-activation of PHD even under pathologic hypoxic conditions, and that the inhibition
of PHD restores EPO production.
3. Erythropoiesis-stimulating agents in CKD-anemia
The standard treatment for CKD-anemia is based on pharmacological intervention, using ESA
and/or iron supplementation, in order to correct and maintain Hb concentration in the range of
10–11.5g/dL [49]. ESA are medicines produced by recombinant DNA technology with similar
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structure and biological activity of EPO. They differ from EPO by the different patterns of
glycosylation that increases their half-life.
The use of ESA has beneficial effects by correcting anemia and their associated symptoms and
improving patients’ quality of life [50, 51]. However, the effects of ESA on the progression of
renal function are controversial. Some studies showed that after starting ESA therapy and
correction of anemia, renal function declines at a slower rate, delaying the need for dialysis in
pre-dialysis patients [52–54]; in opposition, other studies reported that ESA do not signifi-
cantly affect renal function [55, 56].
ESAwere designed to correct anemia, but some evidences showed that these drugs (and EPO)
may act beyond hematopoiesis. Pleiotropic effects have been attributed to EPO and ESA, such
as cytoprotection, anti-apoptosis, anti-inflammatory and angiogenesis [57]. These non-hema-
topoietic actions appear to result from the activation of another EPOR, a heterodimeric recep-
tor constituted by the EPOR homodimer complexed with CD131, the common beta receptor
(βCR) that is involved in granulocyte macrophage colony-stimulating factor, IL-3 and IL-5
signaling [58]. The two EPOR present different affinities for EPO; in erythroid cells picomolar
concentrations of EPO are sufficient to trigger activation of the EPOR homodimer, whereas on
other cells and tissues high local EPO concentrations are needed to activate EPOR heterodimer
[59]. This receptor was detected in several cells and tissues, such as brain (neurons, astrocytes
and microglia), kidney, female reproductive system organs, vascular endothelial cells,
cardiomyocytes, lymphocytes and monocytes, among others [57].
The slower progression of renal dysfunction observed in some CKD patients may result from
renoprotection of ESA therapy. Several studies on acute kidney injury (AKI) reported that a
single dose of recombinant human EPO (rHuEPO) reduces kidney dysfunction through anti-
apoptotic mechanisms and increases NO production, only in intact vessels [60]. ESA therapy
also exerts renoprotective effects by reducing the production of pro-inflammatory cytokines (e.
g., IL-1β and TNF-α), acute phase proteins [e.g., C-reactive protein (CRP)], pro-fibrotic factors
(e.g., TGF-β) and oxidative stress [61]. However, these effects appear to be only achieved with
low doses of ESA, as high doses increase hematocrit and may activate platelets, increasing
their adhesion to the injured endothelium, contributing to hemorheologic changes [60].
Indeed, other side effects are associated with ESA therapy, namely hypertension [62] and
thrombotic events [63].
Despite the benefits of ESA therapy, some concerns have emerged from studies reporting a
high incidence of cardiovascular events and mortality in CKD patients treated with ESA [63,
64], independently of the type of ESA used [65, 66]. Since the introduction of ESA therapy,
several clinical trials aimed to define the better Hb target/ESA dose associated with lower
cardiovascular risk. Indeed, recent studies reported increased cardiovascular risk and death
in patients treated with high ESA doses to achieve higher Hb levels [9, 67–69].
The need for new drugs with lower associated cardiovascular risk opened a growing area of
research. The most promising are the PHD inhibitors (Table 1) with several compounds
already under evaluation in clinical trials. Some of these compounds showed to be well
tolerated, corrected anemia in non-dialysis CKD and incident dialysis patients without
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increasing blood pressure, and also reduced serum hepcidin levels [70–73]. However, regard-
ing their effects in reducing cardiovascular events and slowing the progression of the renal
disease, no data are still available from human studies. Yu et al. [22] showed that the adminis-
tration of PHD inhibitors in a more advanced stage of CKD in the rat reduced renal fibrosis
and protected renal function, whereas the administration in an early stage of CKD promoted
renal fibrosis and exacerbated renal dysfunction. In another strategy to induce EPO produc-
tion, the hydrodynamic gene transfer of a plasmid encoding for EPO in a rat model
overexpressing TGF-β showed that this therapy increased Hb levels but had no effect on
kidney fibrosis or function [74].
4. Hyporesponsiveness to erythropoiesis-stimulating agents in CKD
The majority of CKD patients respond adequately to the currently available ESA therapy, but
5–10% of them do not respond properly, developing hyporesponsiveness to these drugs [75].
According to the KDIGO guidelines [49], CKD patients can present initial or acquired ESA
hyporesponsiveness; in primary hyporesponsiveness patients, after one month of treatment
with adequate weight-based ESA dose, the target Hb concentration is not achieved; in
acquired ESA hyporesponsiveness, after effective treatment with stable ESA dose, achieving
the target Hb concentration, the patient requires two consecutive increases (up to 50% beyond
the stable dose) in ESA dose. Hyporesponsiveness (also widely referred as resistance) to ESA
therapy is associated with a poor outcome, progression of renal disease, sudden death, infec-
tious complications, sudden death and all-cause mortality, mainly due to cardiovascular
events in dialysis patients [76–79]. Several causes are associated with poor response to ESA
therapy, including iron deficiency, inflammation, malnutrition and hyperparathyroidism,
among others [80–82].
4.1. Inflammation
A pro-inflammatory state is a hallmark of CKD, which is due to increased uremic toxins that
induce the production of inflammatory cytokines. Additionally, active infections, the vascular
PHD inhibitor Route administration ClinicalTrials.gov Identifier
Molidustat(BAY85-3934) Oral • NCT02064426
Roxadustat(FG-4592) Oral • NCT01630889
• NCT01887600
Vadadustat(AKB-6548) Oral • NCT01906489
• NCT02648347
• NCT02680574
GSK1278863 Oral • NCT02689206
Table 1. Prolyl-4-hydroxylase (PHD) inhibitors in clinical trials.
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access for hemodialysis (HD) procedure and surgery-related inflammation (vascular surgery
included) can also contribute to inflammation.
The activation of inflammatory cells is also associated with increased oxidative stress, favoring
alterations in red blood cells (RBC) membrane, namely increased phosphatidylserine expo-
sure, increased membrane bound Hb and increased membrane protein band 3 aggregation, all
markers for RBC phagocytosis by macrophages and, thus, for a premature RBC removal [83,
84]. Uremic toxins and pro-inflammatory cytokines also inhibit erythropoiesis, through the
inhibitory effect of IL-1β, TNF-α and IFN-γ on early erythroid cell stages in the bone marrow
[85]. The macrophages of the bone marrow can also be stimulated to increase local pro-
inflammatory cytokines, amplifying the effects of systemic inflammation [86]. In CKD patients,
hepcidin synthesis is enhanced, due to the increase in Il-6, contributing for the limited iron
availability for erythropoiesis [87]. Indeed, CKD patients often present with replete or even
higher iron stores, alongside with inflammation and anemia. A disturbance in the crosstalk
between inflammation, iron metabolism and erythropoiesis may, therefore, favor ESA
hyporesponsiveness. The best predictors for ESA response appear to be IL-6 and CRP [88, 89].
Studies conducted by our group showed that HD patients with poorer response to ESA
present higher levels of pro-inflammatory cytokines [90, 91]; moreover, in studies using a rat
model of chronic renal failure, we found that the severity of the inflammatory state was related
to the reduction in the rHuEPO response [92].
4.2. HIF system in the hyporesponsiveness to erythropoiesis-stimulating agents
Hyporesponsive patients to ESA therapy will develop anemia, and as already referred, it will
promote the progression of renal disease. Tissue hypoxia is amplified according to the severity
of anemia that will reduce O2 availability to body tissues and organs. Within the kidney, the
hypoxic environment leads to the activation of the HIF system, promoting the transcription of
several target genes. In the hypoxic kidney, HIF-1α is essentially expressed in tubular and
glomerular epithelial cells, whereas HIF-2α expression is limited to endothelial and interstitial
cells [93]. The localization of these HIF-α subunits is related to their target genes.
Renal biopsies from CKD patients showed that increased expression of HIF-1α in tubular
epithelial cells is correlated with the stage of renal disease [94]. It was reported that HIF-α
activation in CKD rats presents dynamic changes, as it is activated in early CKD stages and
suppressed in the moderate and end-stage of CKD [95]. Thus, the administration of PHD
inhibitors may improve renal function in more advanced stages of CKD, while in earlier
stages, the PHD inhibitors may increase renal fibrosis due to upregulation of the HIF-1α
subunit [22].
HIF-1α subunit is involved in the activation of pro-fibrotic genes (Figure 1), including the
connective tissue growth factor (CTGF) gene [96]; indeed, the plasma levels of CTGF appear
as a good marker for staging diabetic nephropathy progression [97]. CTGF is a potent
pro-fibrotic factor and a marker of renal fibrosis, increasing ECM production, promoting
EMT, stimulating fibroblasts and potentiating TGF-β signaling [94, 98]. CTGF and TGF-β
present similar effects, but TGF-β also presents immunomodulatory actions [44], recruiting
macrophages to reduce the injury; however, a continuous macrophage activation leads to
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excessive ECM accumulation and increased release of pro-inflammatory cytokines promoting
fibrosis. A study by Basu et al. [99] suggested that TGF-β can in turn induce HIF-1α activation,
which would amplify cell collagen expression contributing to the progression of fibrosis.
There is also a crosstalk between HIF-1α and inflammation (Figure 1). Inflammation favor
tissue hypoxia by several mechanisms including: impaired EPO response, iron mobilization
and bone marrow erythropoiesis, reduced RBC lifespan and also increased demand for O2 by
the inflammatory cells in order to increase pro-inflammatory cytokines. However, it was also
reported that NF-κB can induce HIF-1α activation due to the presence of responsive elements
in the promoter of HIF-1α gene [100]. Another mechanism is the interaction of PHD with some
effectors of the NF-κB pathway, though the exact proteins involved remain unknown [101].
The majority of the studies report a beneficial effect of ESA on renal fibrosis through several
mechanisms [29, 102]. However, recently Gobe et al. [103] reported that in rat model of AKI the
use of higher rHuEPO doses was associated with increased TGF-β expression, oxidative stress
and stimulation of fibroblasts and EMT, contributing to the progression of the disease and
gradual development of CKD in the long term. In this study, the expression of HIF-α subunits
was not reported, as well as the linking between HIF activation and the alterations observed.
Further studies regarding this issue are warranted.
Despite the underlying mechanism, a continuous inflammatory response favoring fibrosis and
a disturbance in the HIF system creates a vicious cycle, contributing to the progression of renal
disease and aggravation of renal anemia [92], and reducing the response to ESA therapy
creating a scenario of hyporesponsiveness to EPO.
5. Conclusions
Anemia is a common complication in CKD patients that can be corrected by the treatment with
ESA. However, the development of a hyporesponse to this therapy was associated with (i) the
progression of the renal disease, due to the amplification of fibrosis and inflammation through
a mechanism involving activation of HIF-1α pathway; (ii) increased risks in the development
of cardiovascular disorder events and all-cause mortality in patients treated with higher doses,
opened a new research field, focused on the design of more effective agents to control anemia
in CKD patients, with less side effects. The use of PHD inhibitors is promising, but further is
needed to confirm their effects in the reduction of cardiovascular events and progression of
renal disease.
Acknowledgements
This work received financial support from FCT/MEC through national funds and co-financed
by FEDER, under the Partnership Agreement PT2020 (UID/MULTI/04378/2013—POCI/01/0145/
FERDER/007728, UID/NEU/04539/2013) and Norte Portugal Regional Coordination and Devel-
opment Commission (CCDR-N)/NORTE2020/Portugal 2020 (Norte-01-0145-FEDER-000024).
Hypoxia and Human Diseases274
Author details
Sandra Ribeiro1, Luís Belo1, Flávio Reis2,3 and Alice Santos-Silva1*
*Address all correspondence to: assilva@ff.up.pt
1 Research Unit on Applied Molecular Biosciences (UCIBIO), REQUIMTE, Department of
Biological Sciences, Laboratory of Biochemistry, Faculty of Pharmacy, University of Porto,
Porto, Portugal
2 Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical
Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra,
Portugal
3 Center for Neuroscience and Cell Biology, Institute for Biomedical Imaging and Life Sciences
(CNC.IBILI) Research Unit, University of Coimbra, Coimbra, Portugal
References
[1] Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with
anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch
Intern Med. 2002;162(12):1401–8. doi:10.1001/archinte.162.12.1401
[2] Fukuhara S, Akizawa T, Morita S, Tsubakihara Y. Understanding measurements of
vitality in patients with chronic kidney disease: connecting a quality-of-life scale to daily
activities. PLoS One. 2012;7(7):e40455. doi:10.1371/journal.pone.0040455
[3] Bonner A, Caltabiano M, Berlund L. Quality of life, fatigue, and activity in Australians
with chronic kidney disease: a longitudinal study. Nurs Health Sci. 2013;15(3):360–7.
doi:10.1111/nhs.12038
[4] Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum
LA. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am
Soc Nephrol. 2009;4(1):48–56. doi:10.2215/CJN.05301107
[5] Garlo K, Williams D, Lucas L, Wong R, Botler J, Abramson S, Parker MG. Severity of
anemia predicts hospital length of stay but not readmission in patients with chronic
kidney disease: a retrospective cohort study. Medicine. 2015;94(25):e964. doi:10.1097/
MD.0000000000000964
[6] Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M,
Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S. Predictors of
rapid progression of glomerular and nonglomerular kidney disease in children and
adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis.
2015;65(6):878–88. doi:10.1053/j.ajkd.2015.01.008
The HIF System Response to ESA Therapy in CKD‐Anemia
http://dx.doi.org/10.5772/64611
275
[7] Chase HS, Hirsch JS, Mohan S, Rao MK, Radhakrishnan J. Presence of early CKD-
related metabolic complications predict progression of stage 3 CKD: a case-controlled
study. BMC Nephrol. 2014;15:187. doi:10.1186/1471-2369-15-187
[8] Phillips JK, Boyd R, Krockenberger MB, Burgio G. Progression of anemia and its rela-
tionship with renal function, blood pressure, and erythropoietin in rats with chronic
kidney disease. Vet Clin Pathol. 2015;44(3):342–54. doi:10.1111/vcp.12276
[9] McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey
AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA.
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes
mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardio-
vascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J.
2011;162(4):748–55. doi:10.1016/j.ahj.2011.07.016
[10] Chang JM, Chen SC, Huang JC, Su HM, Chen HC. Anemia and left ventricular hyper-
trophy with renal function decline and cardiovascular events in chronic kidney disease.
Am J Med Sci. 2014;347(3):183–9. doi:10.1097/MAJ.0b013e31827981be
[11] Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW. The impact
of renal insufficiency and anaemia on survival in patients with cardiovascular disease:
a cohort study. BMC Cardiovasc Disord. 2009;9:51–8. doi:10.1186/1471-2261-9-51
[12] Nseir W, Artul S, Nasrallah N, Mograbi J, Mahamid M. Hospitalization and 1-year all-
cause mortality in type 2 diabetic patients with chronic kidney disease at stages 1 and 2:
effect of mild anemia. J Diabetes. 2015;8(4):502–7. doi:10.1111/1753-0407.12318
[13] Iimori S, Naito S, Noda Y, Nishida H, Kihira H, Yui N, Okado T, Sasaki S, Uchida S, Rai
T. Anaemia management and mortality risk in newly visiting patients with chronic
kidney disease in Japan: the CKD-ROUTE study. Nephrology (Carlton). 2015;20(9):601–
8. doi:10.1111/nep.12493
[14] Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev.
2010;24(1):39–47. doi:10.1016/j.blre.2009.09.001
[15] Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica. 1998;83(8):724–32.
[16] Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75
(7):682–8. doi:10.1038/ki.2008.687
[17] Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K, Nagoshi
N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H,
Yamamoto M, Yanagita M. Dysfunction of fibroblasts of extrarenal origin underlies
renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121(10):3981–90. doi:10.1172/
JCI5730157301
[18] Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M. Isolation and
characterization of renal erythropoietin-producing cells from genetically produced ane-
mia mice. PLoS One. 2011;6(10):e25839. doi:10.1371/journal.pone.0025839
Hypoxia and Human Diseases276
[19] Nagai T, Yasuoka Y, Izumi Y, Horikawa K, Kimura M, Nakayama Y, Uematsu T,
Fukuyama T, Yamazaki T, Kohda Y, Hasuike Y, Nanami M, Kuragano T, Kobayashi N,
Obinata M, Tomita K, Tanoue A, Nakanishi T, Kawahara K, Nonoguchi H. Reevaluation
of erythropoietin production by the nephron. Biochem Biophys Res Commun. 2014;449
(2):222–8. doi:10.1016/j.bbrc.2014.05.014
[20] Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev.
2013;27(1):41–53. doi:10.1016/j.blre.2012.12.003
[21] Sanada S, Toyama H, Ejima Y, Matsubara M. Potential for erythropoietin synthesis in
kidney of uraemic rat alters depending on severity of renal failure. Nephrology
(Carlton). 2009;14(8):735–42. doi:10.1111/j.1440-1797.2009.01110.x
[22] Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X, Jiang S, Ding X. The balance of beneficial and
deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor
in rat remnant kidney depends on the timing of administration. Nephrol Dial Trans-
plant. 2012;27(8):3110–9. doi:10.1093/ndt/gfr754
[23] Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wuthrich RP. Interpretation
of erythropoietin levels in patients with various degrees of renal insufficiency and
anemia. Kidney Int. 2004;66(3):1206–11. doi:10.1111/j.1523-1755.2004.00880.x
[24] Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, Flamant M,
Vrtovsnik F, Stengel B, Froissart M. Timing and determinants of erythropoietin deficiency
in chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):35–42. doi:10.2215/
CJN.04690511
[25] Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in
patients with or without chronic kidney disease. Nephrol Dial Transplant. 2007;22
(10):2900–8. doi:10.1093/ndt/gfm316
[26] Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal
Physiol. 2013;305(9):F1239–48. doi:10.1152/ajprenal.00233.2013
[27] Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, Eckardt KU.
Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc
Nephrol. 2010;21(12):2151–6. doi:10.1681/ASN.2010010116
[28] Garrido P, Ribeiro S, Fernandes J, Vala H, Bronze-da-Rocha E, Rocha-Pereira P, Belo L,
Costa E, Santos-Silva A, Reis F. Iron-hepcidin dysmetabolism, anemia and renal hyp-
oxia, inflammation and fibrosis in the remnant kidney rat model. PLoS One. 2015;10(4):
e0124048. doi:10.1371/journal.pone.0124048
[29] Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, Belo L, Reis F,
Santos-Silva A. Renal risk-benefit determinants of recombinant human erythropoietin
therapy in the remnant kidney rat model—hypertension, anaemia, inflammation and
drug dose. Clin Exp Pharmacol Physiol. 2016;43(3):343–54. doi:10.1111/1440-1681.12541
[30] Lonnberg M, Garle M, Lonnberg L, Birgegard G. Patients with anaemia can shift from
kidney to liver production of erythropoietin as shown by glycoform analysis. J Pharm
Biomed Anal. 2013;81–2:187–92. doi:10.1016/j.jpba.2013.04.009
The HIF System Response to ESA Therapy in CKD‐Anemia
http://dx.doi.org/10.5772/64611
277
[31] de Seigneux S, Lundby AK, Berchtold L, Berg AH, Saudan P, Lundby C. Increased
synthesis of liver erythropoietin with CKD. J Am Soc Nephrol. 2016;27(8):2265–9.
doi:10.1681/ASN.2015050508
[32] Lundby AK, Keiser S, Siebenmann C, Schaffer L, Lundby C. Kidney-synthesized eryth-
ropoietin is the main source for the hypoxia-induced increase in plasma erythropoietin
in adult humans. Eur J Appl Physiol. 2014;114(6):1107–11. doi:10.1007/s00421-014-2844-7
[33] Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, Lee FS. A gain-of-
function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358
(2):162–8. doi:10.1056/NEJMoa073123
[34] Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, Flippin LA,
Arend M, Klaus SJ, Bachmann S. Hypoxia-inducible factor-2alpha-expressing interstitial
fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible
factor stabilization. Kidney Int. 2010;77(4):312–8. doi:10.1038/ki.2009.460
[35] Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL,
Erickson-Miller CL, Haase VH. Hepatic HIF-2 regulates erythropoietic responses to
hypoxia in renal anemia. Blood. 2010;116(16):3039–48. doi:10.1182/blood-2010-02-270322
[36] Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet
V, Johnson RS. Regulation of iron homeostasis by the hypoxia-inducible transcription
factors (HIFs). J Clin Invest. 2007;117(7):1926–32. doi:10.1172/JCI31370
[37] Kumar H, Choi DK. Hypoxia inducible factor pathway and physiological adaptation: a
cell survival pathway? Mediators Inflamm. 2015;2015:584758. doi:10.1155/2015/584758
[38] Heikkila M, Pasanen A, Kivirikko KI, Myllyharju J. Roles of the human hypoxia-induc-
ible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life Sci. 2011;68
(23):3885–901. doi:10.1007/s00018-011-0679-5
[39] Ravenna L, Salvatori L, Russo MA. HIF3alpha: the little we know. FEBS J. 2016;283
(6):993–1003. doi:10.1111/febs.13572
[40] Franzen S, Pihl L, Khan N, Gustafsson H, Palm F. Pronounced kidney hypoxia precedes
albuminuria in type 1 diabetic mice. Am J Physiol Renal Physiol. 2016;310(9):F807–9.
doi:10.1152/ajprenal.00049.2016
[41] KrizW, LeHirM. Pathways to nephron loss starting fromglomerular diseases-insights from
animal models. Kidney Int. 2005;67(2):404–19. doi:10.1111/j.1523-1755.2005.67097.x
[42] Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive
renal disease. Kidney Int. 2008;74(7):860–6. doi:10.1038/ki.2008.351
[43] Thakur S, Viswanadhapalli S, Kopp JB, Shi Q, Barnes JL, Block K, Gorin Y, Abboud HE.
Activation of AMP-activated protein kinase prevents TGF-beta1-induced epithelial-
mesenchymal transition and myofibroblast activation. Am J Pathol. 2015;185(8):2168–
80. doi:10.1016/j.ajpath.2015.04.014
Hypoxia and Human Diseases278
[44] Lopez-Hernandez FJ, Lopez-Novoa JM. Role of TGF-beta in chronic kidney disease:
an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347(1):
141–54. doi:10.1007/s00441-011-1275-6
[45] Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation
in tubulointerstitial damage in mice. J Clin Invest. 2011;121(9):3425–41. doi:10.1172/
JCI57582
[46] LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R.
Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047–53.
doi:10.1038/nm.3218
[47] Brookhart MA, Bradbury BD, Avorn J, Schneeweiss S, Winkelmayer WC. The effect of
altitude change on anemia treatment response in hemodialysis patients. Am J
Epidemiol. 2011;173(7):768–77. doi:10.1093/aje/kwq423
[48] Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, Dan T, Takeda K, Fong
GH, Nishiyama A, Ito S, Miyata T, Yamamoto M, Suzuki N. Erythropoietin synthesis in
renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol.
2016;27(2):428–38. doi:10.1681/ASN.2014121184
[49] Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO
Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl.
2012;2:279–335. doi:10.1038/kisup.2012.37
[50] Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and
quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc
Nephrol. 2009;4(4):726–33. doi:10.2215/CJN.04950908
[51] Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, Agodoa IL. Sys-
tematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis
patients. Nephrol Dial Transplant. 2012;27(6):2418–25. doi:10.1093/ndt/gfr697
[52] Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal
failure patients slows the decline of renal function: a randomized controlled trial. Kid-
ney Int. 2004;66(2):753–60. doi:10.1111/j.1523-1755.2004.00797.x
[53] Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating
protein therapy and the decline of renal function: a retrospective analysis of patients with
chronic kidney disease. Curr Med Res Opin. 2005;21(7):981–7. doi:10.1185/
030079905X49644
[54] Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna
SM, Nuti R. Erythropoietin improves anemia exercise tolerance and renal function and
reduces B-type natriuretic peptide and hospitalization in patients with heart failure and
anemia. Am Heart J. 2006;152(6):1096e9–15. doi:10.1016/j.ahj.2006.08.005
[55] Villar E, Lievre M, Kessler M, Lemaitre V, Alamartine E, Rodier M, Francois M, Zaoui P,
Moranne O, Choukroun G, Guerraoui A, Jolivot A, Janin G, Branger B, Heng AE,
The HIF System Response to ESA Therapy in CKD‐Anemia
http://dx.doi.org/10.5772/64611
279
Boudray C, Bissery A, Rabilloud M, Pouteil-Noble C. Anemia normalization in patients
with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 random-
ized trial. J Diabetes Complications. 2011;25(4):237–43. doi:10.1016/j.jdiacomp.2011.03.003
[56] Covic A, Nistor I, Donciu MD, Dumea R, Bolignano D, Goldsmith D. Erythropoiesis-
stimulating agents (ESA) for preventing the progression of chronic kidney disease: a
meta-analysis of 19 studies. Am J Nephrol. 2014;40(3):263–79. doi:10.1159/000366025
[57] Ogunshola OO, Bogdanova AY. Epo and non-hematopoietic cells: what do we know?
Methods Mol Biol. 2013;982:13–41. doi:10.1007/978-1-62703-308-4_2
[58] Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW,
Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A.
Erythropoietin mediates tissue protection through an erythropoietin and common beta-
subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101(41):14907–12. doi:10.1073/
pnas.0406491101
[59] Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue pro-
tection: a tale of two receptors. Blood Purif. 2010;29(2):86–92. doi:10.1159/000245630
[60] Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr OpinNephrol Hypertens.
2009;18(1):15–20. doi:10.1097/MNH.0b013e32831a9dde.00041552-200901000-00005 [pii]
[61] Bartnicki P, Kowalczyk M, Rysz J. The influence of the pleiotropic action of erythropoi-
etin and its derivatives on nephroprotection. Med Sci Monit. 2013;19:599–605.
doi:10.12659/MSM.889023
[62] Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Effect of eryth-
ropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One.
2013;8(12):e84848. doi:10.1371/journal.pone.0084848
[63] Vinhas J, Barreto C, Assuncao J, Parreira L, Vaz A. Treatment of anaemia with erythro-
poiesis-stimulating agents in patients with chronic kidney disease does not lower mor-
tality and may increase cardiovascular risk: a meta-analysis. Nephron Clin Pract.
2012;121(3–4):c95–101. doi:10.1159/000345158
[64] Jackevicius CA, Fan CS, Warner A. Clinical outcomes of erythropoietin use in heart
failure patients with anemia of chronic kidney disease. J Card Fail. 2014;20(5):327–33.
doi:10.1016/j.cardfail.2014.02.001
[65] Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin
alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm.
2014;36(6):1115–25. doi:10.1007/s11096-014-0023-x
[66] Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM,
Brookhart MA, Goldstein BA. Longer-term outcomes of darbepoetin alfa versus epoetin
alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Am J Kidney Dis. 2015;66(1):106–13. doi:10.1053/j.ajkd.2015.02.339
Hypoxia and Human Diseases280
[67] Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ,
Goodkin DA. The effects of normal as compared with low hematocrit values in patients
with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med.
1998;339(9):584–90. doi:10.1056/NEJM199808273390903
[68] Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU,
Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease
and anemia. N Engl J Med. 2006;355(20):2071–84. doi:10.1056/NEJMoa062276
[69] Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of
anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.
doi:10.1056/NEJMoa065485
[70] Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to
treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin produc-
tion without hypertensive effects. PLoS One. 2014;9(11):e111838. doi:10.1371/journal.
pone.0111838
[71] Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR,
Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH,
Neff TB. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-
4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol.
2016;11(6):982–91. doi:10.2215/CJN.06890615
[72] Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT,
Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB.
Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc
Nephrol. 2016;27(4):1225–33. doi:10.1681/ASN.2015030241
[73] Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay
M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S. A
novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in
CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67(6):861–71.
doi:10.1053/j.ajkd.2015.11.021
[74] Pedersen L, Wogensen L, Marcussen N, Cecchi CR, Dalsgaard T, Dagnaes-Hansen F.
Restoration of haemoglobin level using hydrodynamic gene therapy with erythropoie-
tin does not alleviate the disease progression in an anaemic mouse model for TGFbeta1-
induced chronic kidney disease. PLoS One. 2015;10(6):e0128367. doi:10.1371/journal.
pone.0128367
[75] KDOQI and National Kidney Foundation. KDOQI clinical practice guidelines and clin-
ical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis.
2006;47:S11–145. doi:10.1053/j.ajkd.2006.03.010
[76] Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G,
Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C. Anaemia
and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis
The HIF System Response to ESA Therapy in CKD‐Anemia
http://dx.doi.org/10.5772/64611
281
patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641–8.
doi:10.1093/ndt/gfq802
[77] Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K, Nitta K. Erythropoietin resistance
index and the all-cause mortality of chronic hemodialysis patients. Blood Purif. 2014;37
(2):106–12. doi:10.1159/000358215
[78] Schneider A, Gutjahr-Lengsfeld L, Ritz E, Scharnagl H, Gelbrich G, Pilz S, Macdougall
IC, Wanner C, Drechsler C. Longitudinal assessments of erythropoietin-stimulating
agent responsiveness and the association with specific clinical outcomes in dialysis
patients. Nephron Clin Pract. 2014;128:147–52. doi:10.1159/000367975
[79] Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, De Nicola L.
Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-
dialysis CKD patients. Nephrol Dial Transplant. 2012;27(7):2880–6. doi:10.1093/ndt/gfs007
[80] Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of
epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Trans-
plant. 2007;22(3):794–800. doi:10.1093/ndt/gfl716
[81] Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis ade-
quacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Clin J Am Soc Nephrol. 2010;5(4):576–81. doi:10.2215/CJN.04710709
[82] Sibbel SP, Koro CE, Brunelli SM, Cobitz AR. Characterization of chronic and acute ESA
hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol.
2015;16:144–53. doi:10.1186/s12882-015-0138-x
[83] Nangaku M, Mimura I, Yamaguchi J, Higashijima Y, Wada T, Tanaka T. Role of uremic
toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and
dialysis patients. J Ren Nutr. 2015;25(2):160–3. doi:10.1053/j.jrn.2014.10.011
[84] Straat M, van Bruggen R, de Korte D, Juffermans NP. Red blood cell clearance in
inflammation. Transfus Med Hemother. 2012;39(5):353–61. doi:10.1159/000342229
[85] Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia manage-
ment in hemodialysis patients. Hemodial Int. 2009;13(2):222–34. doi:10.1111/j.1542-
4758.2009.00352.x
[86] Hom J, Dulmovits BM, Mohandas N, Blanc L. The erythroblastic island as an emerging
paradigm in the anemia of inflammation. Immunol Res. 2015;63:75–89. doi:10.1007/
s12026-015-8697-2
[87] Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, Teixeira F,
Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A.
Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in
haemodialysis patients. Acta Haematol. 2009;122(4):226–9. doi:10.1159/000253590
[88] Won HS, Kim HG, Yun YS, Jeon EK, Ko YH, Kim YS, Kim YO, Yoon SA. IL-6 is
an independent risk factor for resistance to erythropoiesis-stimulating agents in
Hypoxia and Human Diseases282
hemodialysis patients without iron deficiency. Hemodial Int. 2012;16(1):31–7.
doi:10.1111/j.1542-4758.2011.00635.x
[89] Kimachi M, Fukuma S, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T, Saito A,
Fukuhara S. Minor elevation in C-reactive protein levels predicts incidence of erythro-
poiesis-stimulating agent hyporesponsiveness among hemodialysis patients. Nephron.
2015;131(2):123–30. doi:10.1159/000438870
[90] Costa E, Rocha S, Rocha-Pereira P, Nascimento H, Castro E, Miranda V, Faria Mdo S,
Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Neutrophil activation and resistance
to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol.
2008;28(6):935–40. doi:10.1159/000142147
[91] do Sameiro-Faria M, Ribeiro S, Costa E, Mendonca D, Teixeira L, Rocha-Pereira P,
Fernandes J, Nascimento H, Kohlova M, Reis F, Amado L, Bronze-da-Rocha E, Miranda
V, Quintanilha A, Belo L, Santos-Silva A. Risk factors for mortality in hemodialysis
patients: two-year follow-up study. Dis Markers. 2013;35(6):791–8. doi:10.1155/2013/
518945
[92] Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, Belo L, Reis F, Santos-
Silva A. Pathological and molecular mechanisms underlying resistance to recombinant
human erythropoietin therapy in the remnant kidney rat model of chronic kidney
disease associated anemia. Biochimie. 2016;125:150–62. doi:10.1016/j.biochi.2016.03.012
[93] Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe
PJ, Maxwell PH, Bachmann S, Eckardt KU. Expression of hypoxia-inducible factor-
1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13
(7):1721–32. doi:10.1097/01.ASN.0000017223.49823.2A
[94] Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y,
Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH. Hypoxia pro-
motes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transi-
tion. J Clin Invest. 2007;117(12):3810–20. doi:10.1172/JCI30487
[95] Yu X, Fang Y, Ding X, Liu H, Zhu J, Zou J, Xu X, Zhong Y. Transient hypoxia-inducible
factor activation in rat renal ablation and reduced fibrosis with L-mimosine. Nephrol-
ogy (Carlton). 2012;17(1):58–67. doi:10.1111/j.1440-1797.2011.01498.x
[96] Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf
is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004;287(6):F1223–32.
doi:10.1152/ajprenal.00245.2004
[97] Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD,
Goldschmeding R, Navis G. Effects of antiproteinuric intervention on elevated connec-
tive tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic
nephropathy. Clin J Am Soc Nephrol. 2011;6(8):1845–50. doi:10.2215/CJN.08190910
[98] Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, Sugaya T, Kopp JB,
Suzuki H. Connective tissue growth factor expressed in tubular epithelium plays a
The HIF System Response to ESA Therapy in CKD‐Anemia
http://dx.doi.org/10.5772/64611
283
pivotal role in renal fibrogenesis. J Am Soc Nephrol. 2005;16(1):133–43. doi:10.1681/
ASN.2004040339
[99] Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, Schnaper HW.
Interdependence of HIF-1alpha and TGF-beta/Smad3 signaling in normoxic and hyp-
oxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol. 2011;300(4):
F898–905. doi:10.1152/ajprenal.00335.2010
[100] Haase VH. Inflammation and hypoxia in the kidney: friends or foes? Kidney Int. 2015;88
(2):213–5. doi:10.1038/ki.2015.89
[101] Scholz CC, Cavadas MA, Tambuwala MM, Hams E, Rodriguez J, von Kriegsheim A,
Cotter P, Bruning U, Fallon PG, Cheong A, Cummins EP, Taylor CT. Regulation of IL-
1beta-induced NF-kappaB by hydroxylases links key hypoxic and inflammatory signal-
ing pathways. Proc Natl Acad Sci USA. 2013;110(46):18490–5. doi:10.1073/pnas.13097
18110
[102] Nasri H. Renal cell protection of erythropoietin beyond correcting the anemia in chronic
kidney disease patients. Cell J. 2014;15(4):378–80.
[103] Gobe GC, Bennett NC, West M, Colditz P, Brown L, Vesey DA, Johnson DW. Increased
progression to kidney fibrosis after erythropoietin is used as a treatment for acute
kidney injury. Am J Physiol Renal Physiol. 2014;306(6):F681–92. doi:10.1152/ajprenal.00
241.2013
Hypoxia and Human Diseases284
